Covid19ABCOVIDNCT04750720
Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection
A study testing Sampling by venipuncture (and eventually by nasopharyngeal swab) in people with Covid19 and SARS-CoV-2, run by Centre Hospitalier Régional d'Orléans at 1 site in France.
Trial summary
The main objective of the study is to describe the temporal curve of COVID-19 IgG and neutralizing antibodies over 24 months in an identified population of patients who presented with SARS-CoV-2 virus infection. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Covid19, SARS-CoV-2
- What is being tested?
- Sampling by venipuncture (and eventually by nasopharyngeal swab)
- Type of treatment
- Vaccines
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 187 participants
- Where
- 1 siteFrance
- Study dates
- 27 Aug 2020to 7 Mar 2022
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age > 18
- Having had a confirmed infection with CoV-2-SARS by RT-PCR and/or serology (IgM and/or IgG specific as significant)
- Being vaccinated against anti-SARS-CoV-2 (vaccine sub-study)
- Benefiting from a Social Security system
- Having consented to participate in the study
- Accepting regular follow-up for 24 months
Who cannot join
- Protected person (under guardianship or trusteeship)
- Person under the protection of justice
- Person unable to express consent
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection According to the Clinical Severity of the Infection.
The main objective of the study is to describe the temporal curve of COVID-19 IgG and neutralizing antibodies over 24 months in an identified population of patients who presented with SARS-CoV-2 virus infection. The secondary objectives are to characterize the kinetics of the antibodies according to the severity of the clinical presentation and patient's characteristics and to determine if the anti-SARS-CoV-2 antibodies retain their neutralizing capacity over time. A sub-study aims to describe the kinetic of neutralizing antibodies (in blood and nasal mucosa) after vaccination.
Read the detailed description
Given the seriousness of the global health consequences of the COVID-19 pandemic and the difficulty of covering the world population with effective vaccination, several questions arise:
- Are the antibodies made by a patient neutralizing and do they protect the individual from further contamination?
- What is the persistence of the antibodies over time according to the clinical presentation, knowing that the very symptomatic forms have developed a much higher level of antibodies than the forms followed only on an outpatient basis and no less severe?
- What is the impact of vaccination (against wild-type virus and emerging variants) ? The investigators propose a single-center, observational study including 300 patients to answer the two questions, by selecting from the file of all the patients having had a positive RT-PCR 3 distinct groups: severe (hospitalized), pauci-symptomatic to moderate (followed in ambulatory only). Note: people living with HIV can be included in each of the groups.
MAIN EVALUATION
> Presence of specific anti-SARS-CoV-2 antibodies in the different study groups at M24 at each of the sampling times (M0, M3, M6, M9, M12, M15, M18, M24)
SECONDARY EVALUATION CRITERIA
- Presence of specific anti-SARS-CoV-2 antibodies in the different groups of the study at M12 and in each of the subgroups at M12 and M24
- Neutralizing capacity of anti-SARS-CoV-2 antibodies to M6, M12 and M24 on the classical strain and the new variants, before and after a possible vaccination against COVID-19
- Measurement of CD8 (CD38 + DR +), CD4 and activated B lymphocytes in culture This will make it possible to answer the question of the persistence or not of an immune response over 24 months, an essential element in the event of seasonal circulation of the virus in the years to come, and of the persistence or not of the neutralizing capacities of these antibodies in the over time, especially when the title approaches the detection threshold.
These information will be decisive in the event of successive waves of the SARS-CoV-2 epidemic given a low level of collective immunity (<10% in France at the end of 2020) in order to know whether previously affected patients are durably protected.
In the context of a lack of vaccine, results from this study would make it possible to select candidates for vaccination from the truly non-immune population.
Vaccine sub-study :
Study of the kinetic of neutralizing antibodies after vaccination :
Volunteers participants, provided they give a special agreement for the vaccine sub-study, will undergo an additional grid of samples to accurately study the kinetic of neutralizing antibodies before and monthly after (up to 6 months) receiving anti-SARS-CoV-2 vaccine (whatever the product used). A special attention will be given to the capacity of their antibodies to neutralize emerging variants. Samples will include blood and possibly nasopharyngeal swabs (not mandatory).
- Conditions
- Covid19, SARS-CoV-2
- Being tested
- Sampling by venipuncture (and eventually by nasopharyngeal swab)
- Keywords
- Covid19, SARS-CoV-2
- Medical subject headings
- COVID-19
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Sampling by venipuncture (and eventually by nasopharyngeal swab)Other
Biological samples :
- Serum and plasma from each donor for the purpose of performing (if applicable) the SARS-CoV-2 serologic test
- PBMC (peripheral blood mononuclear cells)
- Nasopharyngeal samples (not mandatory)
Associated data :
- Demographic data
- Description of clinical manifestations related to SARS-CoV-2 infection
- Notion of hospitalization/ambulatory follow-up
Blood Fractioning
- Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C)
- Separation of PBMC on Lymphoprep and freezing in liquid nitrogen for subsequent analysis of immune system cells
| Study group | Role | What they receive |
|---|---|---|
| Group with biological samples | Experimental | Collection of biological samples (M0, M3, M6, M9, M12, M15, M18, M24) with associated data for the study of the kinetics of antibodies anti COVID-19 in subjects with documented SARS-CoV-2 infection (PCR and/or positive specific serology). In the vaccine sub-study: additional blood and nasopharyngeal samples before and after vaccination, up to 6 months. Receives: Other: Sampling by venipuncture (and eventually by nasopharyngeal swab) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Presence of specific anti-SARS-CoV-2 antibodies
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups at each sampling time
Measured: Month 0
Presence of specific anti-SARS-CoV-2 antibodies
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups at each sampling time
Measured: Month 3
Presence of specific anti-SARS-CoV-2 antibodies
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups at each sampling time
Measured: Month 6
Presence of specific anti-SARS-CoV-2 antibodies
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups at each sampling time
Measured: Month 9
Presence of specific anti-SARS-CoV-2 antibodies
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups at each sampling time
Measured: Month 12
Presence of specific anti-SARS-CoV-2 antibodies
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups at each sampling time
Measured: Month 15
Presence of specific anti-SARS-CoV-2 antibodies
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups at each sampling time
Measured: Month 18
Presence of specific anti-SARS-CoV-2 antibodies
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups at each sampling time
Measured: Month 24
Secondary outcomes (15)
Presence of specific anti-SARS-CoV-2 antibodies
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups
Measured: Month 12
Presence of specific anti-SARS-CoV-2 antibodies in subgroups
Presence of specific anti-SARS-CoV-2 antibodies in each of the subgroups
Measured: Month 12
Presence of specific anti-SARS-CoV-2 antibodies in subgroups
Presence of specific anti-SARS-CoV-2 antibodies in each of the subgroups
Measured: Month 24
Neutralizing capacity of anti-SARS-CoV-2 antibodies
Neutralizing capacity of anti-SARS-CoV-2 antibodies on the classical strain and the new variants, before and after a possible vaccination against COVID-19
Measured: Month 6
Neutralizing capacity of anti-SARS-CoV-2 antibodies
Neutralizing capacity of anti-SARS-CoV-2 antibodies on the classical strain and the new variants, before and after a possible vaccination against COVID-19.
Measured: Month 12
Neutralizing capacity of anti-SARS-CoV-2 antibodies
Neutralizing capacity of anti-SARS-CoV-2 antibodies on the classical strain and the new variants, before and after a possible vaccination against COVID-19.
Measured: Month 24
Measurement of activated CD8 (CD38+DR+) in culture
Measurement of activated CD8 (CD38+DR+) in culture
Measured: Month 6
Measurement of activated CD8 (CD38+DR+) in culture
Measurement of activated CD8 (CD38+DR+) in culture
Measured: Month 12
Measurement of activated CD8 (CD38+DR+) in culture
Measurement of activated CD8 (CD38+DR+) in culture
Measured: Month 24
Measurement of activated CD4 in culture
Measurement of activated CD4 in culture
Measured: Month 6
Measurement of activated CD4 in culture
Measurement of activated CD4 in culture
Measured: Month 12
Measurement of activated CD4 in culture
Measurement of activated CD4 in culture
Measured: Month 24
Measurement of activated B lymphocytes in culture
Measurement of activated B lymphocytes in culture
Measured: Month 6
Measurement of activated B lymphocytes in culture
Measurement of activated B lymphocytes in culture
Measured: Month 12
Measurement of activated B lymphocytes in culture
Measurement of activated B lymphocytes in culture
Measured: Month 24
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Feb 2021
- Study start27 Aug 2020
- Primary completion7 Mar 2022
- Study completion7 Mar 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for Covid19Studies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Collection of biological samples (M0, M3, M6, M9, M12, M15, M18, M24) with associated data for the study of the kinetics of antibodies anti COVID-19 in subjects with documented SARS-CoV-2 infection (PCR and/or positive specific serology)
- Masking
- None (open label)
- Enrolment
- 187 participants (actual)
Sponsor and investigators
- Lead sponsor
- Centre Hospitalier Régional d'Orléans
- Sponsor type
- University, hospital or other
- Collaborators
- Institut Pasteur
- Responsible party
- Sponsor
- Investigators
- Thierry PRAZUCK, MD, Principal investigator, CHU Orléans
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04750720
- Sponsor's protocol ID
- CHRO-2020-12
- Acronym
- ABCOVID
- Status last verified
- Dec 2025
- First submitted
- 9 Feb 2021
- Last updated
- 30 Dec 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brunink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020 Jan;25(3):2000045. doi: 10.2807/1560-7917.ES.2020.25.3.2000045.
PubMed 31992387Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020 May;109:102433. doi: 10.1016/j.jaut.2020.102433. Epub 2020 Feb 26.
PubMed 32113704Fafi-Kremer S, Bruel T, Madec Y, Grant R, Tondeur L, Grzelak L, Staropoli I, Anna F, Souque P, Fernandes-Pellerin S, Jolly N, Renaudat C, Ungeheuer MN, Schmidt-Mutter C, Collongues N, Bolle A, Velay A, Lefebvre N, Mielcarek M, Meyer N, Rey D, Charneau P, Hoen B, De Seze J, Schwartz O, Fontanet A. Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. EBioMedicine. 2020 Sep;59:102915. doi: 10.1016/j.ebiom.2020.102915. Epub 2020 Jul 31.
PubMed 32747185Bolland W, Michel V, Planas D, Hubert M, Staropoli I, Guivel-Benhassine F, Porrot F, N'Debi M, Rodriguez C, Fourati S, Prot M, Planchais C, Hocqueloux L, Simon-Loriere E, Mouquet H, Prazuck T, Pawlotsky J-M, Bruel T, Schwartz O, Buchrieser J. High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1. J Virol. 2024 Jan 23;98(1):e0135123. doi: 10.1128/jvi.01351-23. Epub 2023 Dec 13.
PubMed 38088562Clairon Q, Prague M, Planas D, Bruel T, Hocqueloux L, Prazuck T, Schwartz O, Thiebaut R, Guedj J. Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2. PLoS Comput Biol. 2023 Aug 7;19(8):e1011282. doi: 10.1371/journal.pcbi.1011282. eCollection 2023 Aug.
PubMed 37549192Garcia L, Woudenberg T, Rosado J, Dyer AH, Donnadieu F, Planas D, Bruel T, Schwartz O, Prazuck T, Velay A, Fafi-Kremer S, Batten I, Reddy C, Connolly E, McElheron M, Kennelly SP, Bourke NM, White MT, Pelleau S. Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination. Viruses. 2022 Jul 8;14(7):1491. doi: 10.3390/v14071491.
PubMed 35891471
Study at a glance
From the registry record, last updated by the sponsor on 30 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of the Kinetics of COVID-19 Antibodies for 24 Months in Patients With Confirmed SARS-CoV-2 Infection According to the Clinical Severity of the Infection.
- ClinicalTrials.gov ID
- NCT04750720
- Acronym / sponsor ID
- ABCOVID / CHRO-2020-12
- Conditions
- Covid19, SARS-CoV-2
- Keywords
- Covid19, SARS-CoV-2
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 187 participants (actual)
- Lead sponsor
- Centre Hospitalier Régional d'OrléansUniversity, hospital or other
- Collaborators
- Institut Pasteur
- Study start
- 27 Aug 2020 (actual)
- Primary completion
- 7 Mar 2022 (actual)
- Study completion
- 7 Mar 2022 (actual)
- First posted
- 11 Feb 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The main objective of the study is to describe the temporal curve of COVID-19 IgG and neutralizing antibodies over 24 months in an identified population of patients who presented with SARS-CoV-2 virus infection. The secondary objectives are to characterize the kinetics of the antibodies according to the severity of the clinical presentation and patient's characteristics and to determine if the anti-SARS-CoV-2 antibodies retain their neutralizing capacity over time. A sub-study aims to describe the kinetic of neutralizing antibodies (in blood and nasal mucosa) after vaccination.
Detailed description
Given the seriousness of the global health consequences of the COVID-19 pandemic and the difficulty of covering the world population with effective vaccination, several questions arise:
- Are the antibodies made by a patient neutralizing and do they protect the individual from further contamination?
- What is the persistence of the antibodies over time according to the clinical presentation, knowing that the very symptomatic forms have developed a much higher level of antibodies than the forms followed only on an outpatient basis and no less severe?
- What is the impact of vaccination (against wild-type virus and emerging variants) ? The investigators propose a single-center, observational study including 300 patients to answer the two questions, by selecting from the file of all the patients having had a positive RT-PCR 3 distinct groups: severe (hospitalized), pauci-symptomatic to moderate (followed in ambulatory only). Note: people living with HIV can be included in each of the groups.
MAIN EVALUATION
> Presence of specific anti-SARS-CoV-2 antibodies in the different study groups at M24 at each of the sampling times (M0, M3, M6, M9, M12, M15, M18, M24)
SECONDARY EVALUATION CRITERIA
- Presence of specific anti-SARS-CoV-2 antibodies in the different groups of the study at M12 and in each of the subgroups at M12 and M24
- Neutralizing capacity of anti-SARS-CoV-2 antibodies to M6, M12 and M24 on the classical strain and the new variants, before and after a possible vaccination against COVID-19
- Measurement of CD8 (CD38 + DR +), CD4 and activated B lymphocytes in culture This will make it possible to answer the question of the persistence or not of an immune response over 24 months, an essential element in the event of seasonal circulation of the virus in the years to come, and of the persistence or not of the neutralizing capacities of these antibodies in the over time, especially when the title approaches the detection threshold.
These information will be decisive in the event of successive waves of the SARS-CoV-2 epidemic given a low level of collective immunity (<10% in France at the end of 2020) in order to know whether previously affected patients are durably protected.
In the context of a lack of vaccine, results from this study would make it possible to select candidates for vaccination from the truly non-immune population.
Vaccine sub-study :
Study of the kinetic of neutralizing antibodies after vaccination :
Volunteers participants, provided they give a special agreement for the vaccine sub-study, will undergo an additional grid of samples to accurately study the kinetic of neutralizing antibodies before and monthly after (up to 6 months) receiving anti-SARS-CoV-2 vaccine (whatever the product used). A special attention will be given to the capacity of their antibodies to neutralize emerging variants. Samples will include blood and possibly nasopharyngeal swabs (not mandatory).
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Collection of biological samples (M0, M3, M6, M9, M12, M15, M18, M24) with associated data for the study of the kinetics of antibodies anti COVID-19 in subjects with documented SARS-CoV-2 infection (PCR and/or positive specific serology)
| Arm | Type | Receives |
|---|---|---|
| Group with biological samples | Experimental | Other: Sampling by venipuncture (and eventually by nasopharyngeal swab)Collection of biological samples (M0, M3, M6, M9, M12, M15, M18, M24) with associated data for the study of the kinetics of antibodies anti COVID-19 in subjects with documented SARS-CoV-2 infection (PCR and/or positive specific serology). In the vaccine sub-study: additional blood and nasopharyngeal samples before and after vaccination, up to 6 months. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (6 listed)
- Age > 18
- Having had a confirmed infection with CoV-2-SARS by RT-PCR and/or serology (IgM and/or IgG specific as significant)
- Being vaccinated against anti-SARS-CoV-2 (vaccine sub-study)
- Benefiting from a Social Security system
- Having consented to participate in the study
Key exclusion criteria (3 listed)
- Protected person (under guardianship or trusteeship)
- Person under the protection of justice
- Person unable to express consent
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Sampling by venipuncture (and eventually by nasopharyngeal swab)Biological samples : * Serum and plasma from each donor for the purpose of performing (if applicable) the SARS-CoV-2 serologic test * PBMC (peripheral blood mononuclear cells) * Nasopharyngeal samples (not mandatory) Associated data : * Demographic data * Description of clinical manifestations related to SARS-CoV-2 infection * Notion of hospitalization/ambulatory follow-up Blood Fractioning * Serum and plasma aliquoted and stored under 250, 500 and 1000 µL (at -80°C) * Separation of PBMC on Lymphoprep and freezing in liquid nitrogen for subsequent analysis of immune system cells | Other | Group with biological samples |
Primary outcome
Presence of specific anti-SARS-CoV-2 antibodies
Time frame: Month 0
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups at each sampling time
Presence of specific anti-SARS-CoV-2 antibodies
Time frame: Month 3
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups at each sampling time
Presence of specific anti-SARS-CoV-2 antibodies
Time frame: Month 6
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups at each sampling time
Presence of specific anti-SARS-CoV-2 antibodies
Time frame: Month 9
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups at each sampling time
Presence of specific anti-SARS-CoV-2 antibodies
Time frame: Month 12
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups at each sampling time
Presence of specific anti-SARS-CoV-2 antibodies
Time frame: Month 15
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups at each sampling time
Presence of specific anti-SARS-CoV-2 antibodies
Time frame: Month 18
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups at each sampling time
Presence of specific anti-SARS-CoV-2 antibodies
Time frame: Month 24
Presence of specific anti-SARS-CoV-2 antibodies in the different study groups at each sampling time
15 secondary outcomes
Presence of specific anti-SARS-CoV-2 antibodies
Time frame: Month 12
Presence of specific anti-SARS-CoV-2 antibodies in subgroups
Time frame: Month 12
Presence of specific anti-SARS-CoV-2 antibodies in subgroups
Time frame: Month 24
Neutralizing capacity of anti-SARS-CoV-2 antibodies
Time frame: Month 6
Neutralizing capacity of anti-SARS-CoV-2 antibodies
Time frame: Month 12
Neutralizing capacity of anti-SARS-CoV-2 antibodies
Time frame: Month 24
Measurement of activated CD8 (CD38+DR+) in culture
Time frame: Month 6
Measurement of activated CD8 (CD38+DR+) in culture
Time frame: Month 12
Measurement of activated CD8 (CD38+DR+) in culture
Time frame: Month 24
Measurement of activated CD4 in culture
Time frame: Month 6
Measurement of activated CD4 in culture
Time frame: Month 12
Measurement of activated CD4 in culture
Time frame: Month 24
Measurement of activated B lymphocytes in culture
Time frame: Month 6
Measurement of activated B lymphocytes in culture
Time frame: Month 12
Measurement of activated B lymphocytes in culture
Time frame: Month 24
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Dec 2025.
- Background: PubMed 31992387Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brunink S, Schneider J, Schmidt ML, Mulders DG, Haagmans BL, van der Veer B, van den Brink S, Wijsman L, Goderski G, Romette JL, Ellis J, Zambon M, Peiris M, Goossens H, Reusken C, Koopmans MP, Drosten C. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020 Jan;25(3):2000045. doi: 10.2807/1560-7917.ES.2020.25.3.2000045.
- Background: PubMed 32113704Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 2020 May;109:102433. doi: 10.1016/j.jaut.2020.102433. Epub 2020 Feb 26.
- Background: PubMed 32747185Fafi-Kremer S, Bruel T, Madec Y, Grant R, Tondeur L, Grzelak L, Staropoli I, Anna F, Souque P, Fernandes-Pellerin S, Jolly N, Renaudat C, Ungeheuer MN, Schmidt-Mutter C, Collongues N, Bolle A, Velay A, Lefebvre N, Mielcarek M, Meyer N, Rey D, Charneau P, Hoen B, De Seze J, Schwartz O, Fontanet A. Serologic responses to SARS-CoV-2 infection among hospital staff with mild disease in eastern France. EBioMedicine. 2020 Sep;59:102915. doi: 10.1016/j.ebiom.2020.102915. Epub 2020 Jul 31.
- Derived from this study: PubMed 38088562Bolland W, Michel V, Planas D, Hubert M, Staropoli I, Guivel-Benhassine F, Porrot F, N'Debi M, Rodriguez C, Fourati S, Prot M, Planchais C, Hocqueloux L, Simon-Loriere E, Mouquet H, Prazuck T, Pawlotsky J-M, Bruel T, Schwartz O, Buchrieser J. High fusion and cytopathy of SARS-CoV-2 variant B.1.640.1. J Virol. 2024 Jan 23;98(1):e0135123. doi: 10.1128/jvi.01351-23. Epub 2023 Dec 13.
- Derived from this study: PubMed 37549192Clairon Q, Prague M, Planas D, Bruel T, Hocqueloux L, Prazuck T, Schwartz O, Thiebaut R, Guedj J. Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2. PLoS Comput Biol. 2023 Aug 7;19(8):e1011282. doi: 10.1371/journal.pcbi.1011282. eCollection 2023 Aug.
- Derived from this study: PubMed 35891471Garcia L, Woudenberg T, Rosado J, Dyer AH, Donnadieu F, Planas D, Bruel T, Schwartz O, Prazuck T, Velay A, Fafi-Kremer S, Batten I, Reddy C, Connolly E, McElheron M, Kennelly SP, Bourke NM, White MT, Pelleau S. Kinetics of the SARS-CoV-2 Antibody Avidity Response Following Infection and Vaccination. Viruses. 2022 Jul 8;14(7):1491. doi: 10.3390/v14071491.
Related trials for Covid19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Thierry PRAZUCK, MD principal investigator
CHU Orléans
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Sampling by venipuncture (and eventually by nasopharyngeal swab) in people with Covid19 and SARS-CoV-2, run by Centre Hospitalier Régional d'Orléans at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Presence of specific anti-SARS-CoV-2 antibodies (time frame: Month 0). The study lists 8 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04750720, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Dec 2025.